Do cannabis and CBD help menopause symptoms?

This is not medical advice — it is general information based on what you searched for that may help.

General information based on published sources and the symptoms you searched for. This isn't medical or legal advice, a diagnosis or a treatment plan. Please consult a doctor about your own symptoms. If your symptoms are severe or sudden, seek urgent care.

This page may not apply to you if:

Cannabis and CBD products are unregulated for purity and dosing in most markets and can interact with other medications

Our verdict: Not recommended as a treatment for hot flashes (Level II).

Cannabis and CBD (cannabidiol) products are increasingly marketed for perimenopause and menopause symptoms, including hot flashes, sleep, and mood. After reviewing the randomized trial literature in its 2023 Nonhormone Therapy Position Statement, The Menopause Society placed cannabinoids in the not recommended category for vasomotor symptoms (Level II).

Two separate problems: evidence, and product quality

This verdict covers effectiveness for hot flashes specifically — the trial evidence doesn't support cannabinoids as a reliable treatment for vasomotor symptoms. There's a second, practical issue worth knowing about too: cannabis and CBD products are largely unregulated for purity and dosing accuracy in most markets, meaning what's on the label doesn't always match what's in the product. They can also interact with other medications you may be taking.

Together, that's an unproven benefit combined with real variability in what you're actually getting — worth weighing carefully before spending money on a product marketed this way.

What actually has evidence behind it

Hormone therapy: Most effective treatment for vasomotor symptoms without contraindications.
CBT and clinical hypnosis: Level I, with real benefits for both mood and sleep.
Non-hormonal prescriptions: SSRIs/SNRIs, gabapentin, NK3 antagonists, all Level I.

If insomnia or anxiety are what you were hoping CBD would help with, those symptom pages cover options graded for those specific outcomes. Log what you're actually experiencing in our private symptom tracker before trying any new product.

If I was considering CBD mainly for sleep or anxiety rather than hot flashes, is there a better-supported option for those specific symptoms?
Could a CBD or cannabis product I'm already taking interact with any of my current medications?

Where are you right now?

Still tracking

Not sure if your symptoms fit? Start tracking your daily patterns.

Log and spot your patterns with the symptom checklist →

Ready to talk to a doctor

Have an upcoming appointment? Bring structured questions and your history.

Prepare your 10-minute doctor appointment questions →

Already on treatment

Evaluating your response or wondering what to adjust next?

Explore evidence-graded treatment and lifestyle options →

Questions people ask

Does CBD or cannabis help with hot flashes?

According to The Menopause Society's 2023 review, no — cannabinoids are classified as not recommended for vasomotor symptoms (Level II), meaning the trial evidence doesn't support them as an effective hot-flash treatment.

Are cannabis and CBD products safe to use for menopause symptoms generally?

Beyond the lack of evidence for hot flashes specifically, cannabis and CBD products are largely unregulated for purity and dosing accuracy in most markets, and can interact with other medications. That combination of unproven benefit and real variability in product quality is worth weighing carefully before trying one.

References

Shufelt CL, Brown V, Carpenter JS et al.. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause (The North American Menopause Society, now The Menopause Society), 2023.

The 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause (The North American Menopause Society, now The Menopause Society), 2022. Funding: Funded by donations to the NAMS Education & Research Fund; the statement reports no commercial support. Individual panel disclosures not yet reviewed..